113 related articles for article (PubMed ID: 8907719)
1. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs.
Kiriyama A; Sugahara M; Yoshikawa Y; Kiso Y; Takada K
Biopharm Drug Dispos; 1996 Mar; 17(2):125-34. PubMed ID: 8907719
[TBL] [Abstract][Full Text] [Related]
2. Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: effect of solvent.
Sugahara M; Kiriyama A; Hamada Y; Kiso Y; Takada K
Biopharm Drug Dispos; 1995 May; 16(4):269-77. PubMed ID: 7548776
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations.
Kiriyama A; Mimoto T; Kisanuki S; Kiso Y; Takada K
Biopharm Drug Dispos; 1993 Nov; 14(8):697-707. PubMed ID: 8305629
[TBL] [Abstract][Full Text] [Related]
4. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
5. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
[TBL] [Abstract][Full Text] [Related]
6. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
Lin JH; Chen IW; Vastag KJ; Ostovic D
Drug Metab Dispos; 1995 Jul; 23(7):730-5. PubMed ID: 7587962
[TBL] [Abstract][Full Text] [Related]
7. Development of a colonic release capsule dosage form and the absorption of insulin.
Kraeling ME; Ritschel WA
Methods Find Exp Clin Pharmacol; 1992 Apr; 14(3):199-209. PubMed ID: 1378164
[TBL] [Abstract][Full Text] [Related]
8. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.
Fung HB; Kirschenbaum HL; Hameed R
Clin Ther; 2000 May; 22(5):549-72. PubMed ID: 10868554
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations.
Kiriyama A; Mimoto T; Kiso Y; Takada K
Biopharm Drug Dispos; 1993 Apr; 14(3):199-207. PubMed ID: 8490108
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
[TBL] [Abstract][Full Text] [Related]
11. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration.
Kiriyama A; Fujita K; Takemura S; Kuramoto H; Kiso Y; Takada K
Biopharm Drug Dispos; 1994 Oct; 15(7):617-26. PubMed ID: 7849237
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
Mueller BU; Anderson BD; Farley MQ; Murphy R; Zuckerman J; Jarosinski P; Godwin K; McCully CL; Mitsuya H; Pizzo PA; Balis FM
Antimicrob Agents Chemother; 1998 Jul; 42(7):1815-8. PubMed ID: 9661027
[TBL] [Abstract][Full Text] [Related]
13. Plasma profiles of lycopene after single oral and intravenous administrations in dogs.
Vertzoni M; Valsami G; Reppas C
J Pharm Pharmacol; 2006 Sep; 58(9):1211-7. PubMed ID: 16945179
[TBL] [Abstract][Full Text] [Related]
14. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs.
Takaya T; Ikeda C; Imagawa N; Niwa K; Takada K
J Pharm Pharmacol; 1995 Jun; 47(6):474-8. PubMed ID: 7545751
[TBL] [Abstract][Full Text] [Related]
15. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes.
Kiriyama A; Nishiura T; Yamaji H; Takada K
Antimicrob Agents Chemother; 1999 Mar; 43(3):549-56. PubMed ID: 10049266
[TBL] [Abstract][Full Text] [Related]
16. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
17. [Some factors influencing the bioavailability of zinc in oral pharmaceutical dosage forms].
Neve J; Hanocq M; Peretz A; Abi Khalil F; Pelen F
J Pharm Belg; 1993; 48(1):5-11. PubMed ID: 8483101
[TBL] [Abstract][Full Text] [Related]
18. Effect of adsorbents on the absorption of lansoprazole with surfactant.
Ito Y; Arai H; Uchino K; Iwasaki K; Shibata N; Takada K
Int J Pharm; 2005 Jan; 289(1-2):69-77. PubMed ID: 15652200
[TBL] [Abstract][Full Text] [Related]
19. Fast-dissolving microparticles fail to show improved oral bioavailability.
Wong SM; Kellaway IW; Murdan S
J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral adenosine 5'-triphosphate and adenosine in enteric-coated capsules on indomethacin-induced permeability changes in the human small intestine: a randomized cross-over study.
Bours MJ; Bos HJ; Meddings JB; Brummer RJ; van den Brandt PA; Dagnelie PC
BMC Gastroenterol; 2007 Jun; 7():23. PubMed ID: 17578566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
